Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. | 13,018,965 | reported | 21 Nov 2025 | tx 1+2,068,965 |
| Acumen Pharmaceuticals, Inc. | 1,124,729 | reported | 06 Jul 2021 | tx 5+3,417,075−2,967,075 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 21 Nov 2025 | PURCHASE | Inhibikase Therapeutics, Inc. | 2,068,965 | 1.45 USD | first after silence |
| 06 Jul 2021 | CONVERSION | Acumen Pharmaceuticals, Inc. | 1,842,346 | — | |
| 06 Jul 2021 | CONVERSION | Acumen Pharmaceuticals, Inc. | 1,124,729 | — | |
| 06 Jul 2021 | PURCHASE | Acumen Pharmaceuticals, Inc. | 450,000 | 14.88 USD | |
| 06 Jul 2021 | CONVERSION | Acumen Pharmaceuticals, Inc. | 1,842,346 | — | deriv |
| 06 Jul 2021 | CONVERSION | Acumen Pharmaceuticals, Inc. | 1,124,729 | — | deriv |
1 purchase reported after at least 12 months of silence — most recent on 21 Nov 2025.